Research programme: monoclonal antibodies - Humabs BioMed

Drug Profile

Research programme: monoclonal antibodies - Humabs BioMed

Alternative Names: RVC 20; RVC 58

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Humabs BioMed
  • Developer Humabs BioMed; Swiss Tropical and Public Health Institute; University of California at Berkeley
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Infections

Highest Development Phases

  • Preclinical Dengue; Ebola virus infections; Hepatitis B; Influenza B virus infections; Metapneumovirus infections; Middle East respiratory syndrome coronavirus; Norovirus infections; Rabies; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Staphylococcal infections; Zika virus infection
  • Research Campylobacter infections; Cancer; Escherichia coli infections; Herpes simplex virus infections

Most Recent Events

  • 16 May 2017 Early research in Campylobacter infections in Switzerland (Parenteral)
  • 16 May 2017 Early research in Escherichia coli infections in Switzerland (Parenteral)
  • 14 Jul 2016 Preclinical trials in Zika virus infection in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top